%0 Journal Article %A Paul Henriot %A Mathieu Castry %A Liem Binh Luong Nguyen %A Yusuke Shimakawa %A Kévin Jean %A Laura Temime %T Risk of HCV infection associated with hospital-based invasive procedures: a systematic review and meta-analysis %D 2021 %R 10.1101/2021.11.04.21265936 %J medRxiv %P 2021.11.04.21265936 %X Background Healthcare settings, where invasive procedures are frequently performed, may play an important role in the transmission dynamics of blood-borne pathogens when compliance with infection control precautions remains suboptimal. This study aims at better understanding and quantifying the role of hospital-based invasive procedures on hepatitis C virus (HCV) transmission.Methods We conducted a systematic review and meta-analysis to identify recent studies reporting association measures of HCV infection risk that are linked to iatrogenic procedures performed in hospital settings. Based on expert opinion, invasive procedures were categorized into 10 groups for which pooled measures were calculated. Finally, the relationship between pooled measures and the country-level HCV prevalence or the Healthcare Access and Quality (HAQ) index was assessed in meta-regressions.Findings A total of 71 studies were included in the analysis. The most frequently evaluated procedures were blood transfusion and surgery (60 and 37 studies, respectively). The pooled odds ratio (OR) of HCV infection varied widely, ranging from 1·46 (95%CI: 1·14-1·88) for dental procedures to 3·84 (2·07-7·12) for wound care. The OR for blood transfusion was higher for transfusions performed before 1998 (3·77, 2·42-5·88) than for those without a specified date (2·26, 1·81-2·81). Finally, the country-level overall risk for all procedures was significantly associated with HCV prevalence, but not with the HAQ index. In procedure-specific analyses, the HCV infection risk was significantly negatively associated with the HAQ for endoscopy and positively associated with HCV prevalence for endoscopy and surgery.Interpretation Various invasive procedures were documented to be significantly associated with HCV infection. Our results provide a ranking of procedures in terms of HCV risk that may be used for prioritization of infection control measures, especially in high HCV prevalence settings.Funding INSERM-ANRS (France Recherche Nord and Sud Sida-HIV Hépatites)Research in contextEvidence before this studyEvidence before this study We searched PubMed for systematic review or meta-analyses articles published between Jan 1, 2000 and Oct 31, 2021, and focused on iatrogenic risk factors associated with HCV infection in hospitalized patients, using “hepatitis C”, “risk” and “hospital” as keywords. We found a single comprehensive meta-analysis assessing HCV risk factors and reporting pooled risks estimates for hospital-based procedures. However, this meta-analysis was not specific to in-hospital procedures, based on articles published between 1989 and 2013, and did not strictly follow the PRISMA guidelines.Added value of this studyAdded value of this study Our study presents an up-to-date assessment of the risks of HCV infection associated with different hospital-based procedures. Results suggest that iatrogenic HCV infection risk remains important, in studies that were recently conducted. We underline the importance of this risk in high prevalence settings and provide a potential prioritization of procedures associated with HCV infection that may help implementing infection control measures efficiently.Implications of all the available evidenceImplications of all the available evidence This study shows that iatrogenic procedures remain at risk of transmitting blood-borne pathogens, in particular HCV. Despite the availability of highly efficacious direct acting antivirals to treat chronic HCV infection, the prevention of iatrogenic HCV infection, through strictly complying with the established standard precautions, remains essential. These results could be used in modelling studies to help find optimal and efficient control measures to reduce in-hospital HCV transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by INSERM-ANRS (France Recherche Nord and Sud Sida-HIV Hepatites), grant number 12320 B115.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the present work is available in the supplementary material. %U https://www.medrxiv.org/content/medrxiv/early/2021/11/10/2021.11.04.21265936.full.pdf